Drug intelligence / Profile preview

EV-CURIS

Development stage: Unknown
Lead developer: Biocuris Pharma
Modality: Small Molecules
Administration: Oral

Overview

EV-CURIS is a marketed fixed-dose combination product developed by Biocuris Pharma, primarily used for managing hormonal imbalances and skin health. It contains Evening Primrose Oil, which is a rich source of gamma-linolenic acid (GLA), and Vitamin E (Tocopherol). GLA is an essential fatty acid that serves as a precursor to prostaglandin E1 (PGE1), which possesses anti-inflammatory properties and helps alleviate symptoms of premenstrual syndrome (PMS) and cyclical mastalgia. Vitamin E is included as a lipid-soluble antioxidant that protects the polyunsaturated fatty acids in the oil from oxidation and supports overall cellular health. The product is typically formulated as softgel capsules for oral administration.

Brand names: EV-CURIS

Targets

Prostanoid R (Prostanoid receptors)

Beyond the preview

Go deeper on EV-CURIS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EV-CURIS.

Explore the full profile